Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 3/20 | 0.41 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.41 |
| ▸ | NCF1 | P14598 | 1/20 | 0.41 |
| ▸ | HTR3A | P46098 | 5/20 | 0.40 |
| ▸ | HTR3E | A5X5Y0 | 2/20 | 0.40 |
| ▸ | HTR3B | O95264 | 2/20 | 0.40 |
| ▸ | HTR1A | P08908 | 2/20 | 0.40 |
| ▸ | HTR2C | P28335 | 2/20 | 0.40 |
| ▸ | HTR3D | Q70Z44 | 2/20 | 0.40 |
| ▸ | HTR3C | Q8WXA8 | 2/20 | 0.40 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4553023 | 0.84 | TDP1 (0.46) | TDP1HTTHSD17B10POLB | |
| SCHEMBL29991297 | 0.82 | GAA (0.47) | TDP1HTTHSD17B10MKNK1POLB | |
| SCHEMBL739312 | 0.82 | GAA (0.47) | TDP1HTTHSD17B10MKNK1POLB | |
| SCHEMBL28536392 | 0.79 | HRH4 (0.47) | TDP1HTTHTR3AHTR3EHTR3B | |
| SCHEMBL11609822 | 0.79 | HTT (0.54) | TDP1HTTMAPK1MKNK1POLB | |
| SCHEMBL4558381 | 0.78 | HTR2C (0.45) | HTR3AHTR3EHTR3BHTR1AHTR2C | |
| SCHEMBL21047640 | 0.78 | MKNK1 (0.42) | TDP1HTTHSD17B10MKNK1POLB | |
| SCHEMBL10384099 | 0.77 | MKNK1 (0.43) | TDP1HTTHTR3AHTR3EHTR3B | |
| SCHEMBL7196401 | 0.77 | TDP1 (0.58) | TDP1HTTMAPK1HSD17B10POLB | |
| Fluoride SCHEMBL7486853 | 0.76 | HTT (0.54) | TDP1HTTMAPK1MKNK1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0505543-A1 | NOVEL p-SUBSTITUTED PHENYL 4-OXYBUTANE AMINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | LABORATOIRE THERAMEX (MC) | 1992-09-30 | — | — | EP | claimed |
| WO-1992006977-A1 | NOVEL p-SUBSTITUTED PHENYL 4-OXYBUTANE AMINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | LABORATOIRE THERAMEX S.A. (MC) | 1992-04-30 | — | — | WO | claimed |
| US-20190292189-A1 | LIM KINASE INHIBITORS | VIRONGY, LLC | 2019-09-26 | — | — | US | disclosed |
| EP-3252045-B1 | CYANOGUANIDINES AND THEIR USE AS ANTIVIRAL AGENTS | ABBVIE INC (US) | 2019-09-04 | — | — | EP | disclosed |
| US-10112911-B2 | Substituted cyanoguanidines as oral anti-virals | ABBVIE INC. (US) | 2018-10-30 | — | — | US | disclosed |
| EP-2867221-B1 | CYANOGUANIDINES AND THEIR SUE AS ANTIVIRAL AGENTS. | ABBVIE INC (US) | 2018-01-17 | — | — | EP | disclosed |
| EP-3252045-A1 | CYANOGUANIDINES AND THEIR USE AS ANTIVIRAL AGENTS | AbbVie Inc. (US) | 2017-12-06 | — | — | EP | disclosed |
| WO-2017201187-A1 | LIM KINASE INHIBITORS | VIRONGY, LLC (US) | 2017-11-23 | — | — | WO | disclosed |
| US-9415047-B2 | Use of benzo five-membered nitrogen heterocyclic piperazine or piperidine derivatives | Liaoning Emmy Biological Pharmaceutical Co., Ltd. (CN) | 2016-08-16 | — | — | US | disclosed |
| US-20150322045-A1 | CYANOGUANIDINES AND USES THEREOF | ABBVIE INC. | 2015-11-12 | — | — | US | disclosed |
| US-20150297586-A1 | USE OF BENZO FIVE-MEMBERED NITROGEN HETEROCYCLIC PIPERAZINE OR PIPERIDINE DERIVATIVES | Liaoning Emmy Biological Pharmaceutical Co., Ltd. (CN) | 2015-10-22 | — | — | US | disclosed |
| EP-1758895-A1 | GONADOTROPIN RELEASING HORMONE RECEPTOR ANTAGONISTS | Wyeth a Corporation of the State of Delaware (US) | 2007-03-07 | — | — | EP | disclosed |
| EP-1747258-A2 | CLEANSING WIPES HAVING A COVALENTLY BOUND OLEOPHILIC COATING, THEIR USE AND PROCESSES FOR THEIR MANUFACTURE | Reckitt Benckiser (UK) LIMITED (GB) | 2007-01-31 | — | — | EP | disclosed |
| EP-1744836-A2 | PROCESS AND APPARATUS FOR PLASMA COATING, SUBSTRATES COATED BY THIS METHOD OR APPARATUS | Dow Corning Ireland Limited (IE) | 2007-01-24 | — | — | EP | disclosed |
| US-20060019965-A1 | Gonadotropin releasing hormone receptor antagonists | WYETH (US) | 2006-01-26 | — | — | US | disclosed |
| WO-2006009734-A1 | GONADOTROPIN RELEASING HORMONE RECEPTOR ANTAGONISTS | WYETH (US) | 2006-01-26 | — | — | WO | disclosed |
| WO-2005123891-A2 | CLEANSING WIPES HAVING A COVALENTLY BOUND OLEOPHILIC COATING, THEIR USE AND PROCESSES FOR THEIR MANUFACTURE | RECKITT BENCKISER (UK) LIMITED (GB) | 2005-12-29 | — | — | WO | disclosed |
| WO-2005110626-A2 | PROCESS AND APPARATUS FOR PLASMA COATING, SUBSTRATES COATED BY THIS METOD OR APPARATUS | DOW CORNING IRELAND LIMITED (IE) | 2005-11-24 | — | — | WO | disclosed |
| US-6548505-B1 | Protecting biological materials from damage caused by radiation; side effect reduction during radiotherapy or chemotherapy; indole, benzimidazole, benzoxazole or benzothiazole compounds substituted with 4-alkylpiperazino | PETER MACCALLUM CANCER INSTITUTE (AU) | 2003-04-15 | — | — | US | disclosed |
| EP-0580541-B1 | Piperidine derivatives of benzimidazole as antihistaminic and antiallergic agents | ESPANOLA PROD QUIMICOS (ES) | 1999-10-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150322045-A1 | CYANOGUANIDINES AND USES THEREOF | GMPS, RNGTT, RNMT | TDP1 1456/4885HTT 1799/4885ADRB2 3831/4885 |
| US-20060019965-A1 | Gonadotropin releasing hormone receptor antagonists | GNRHR, GHRHR, LHCGR | TDP1 4306/4885HTT 439/4885ADRB2 375/4885 |
| US-10112911-B2 | Substituted cyanoguanidines as oral anti-virals | RNGTT, GMPS, RNMT | TDP1 1723/4885HTT 2627/4885ADRB2 3395/4885 |
| US-20150297586-A1 | USE OF BENZO FIVE-MEMBERED NITROGEN HETEROCYCLIC PIPERAZINE OR PIPERIDINE DERIVATIVES | P2RX5, TBXA2R, CYP3A5 | TDP1 2634/4885HTT 2390/4885ADRB2 64/4885 |
| US-20190292189-A1 | LIM KINASE INHIBITORS | LIMK1, LIMK2, LIMA1 | TDP1 1898/4885HTT 2181/4885ADRB2 4138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.